Aldeyra Therapeutics Croissance future

Future contrôle des critères 5/6

Aldeyra Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 62.3% et de 49.4% par an respectivement. Le BPA devrait croître de de 62.4% par an. Le rendement des capitaux propres devrait être -27.2% dans 3 ans.

Informations clés

62.3%

Taux de croissance des bénéfices

62.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices	27.6%
Taux de croissance des recettes	49.4%
Rendement futur des capitaux propres	-27.2%
Couverture par les analystes	Good
Dernière mise à jour	16 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

Dec 22

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ALDX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	75	9	-40	N/A	5
12/31/2025	33	-39	-62	N/A	7
12/31/2024	25	-27	-47	N/A	8
6/30/2024	N/A	-38	-31	-31	N/A
3/31/2024	N/A	-30	-31	-31	N/A
12/31/2023	N/A	-38	-30	-30	N/A
9/30/2023	N/A	-46	-42	-42	N/A
6/30/2023	N/A	-52	-47	-47	N/A
3/31/2023	N/A	-61	-53	-53	N/A
12/31/2022	N/A	-62	-57	-57	N/A
9/30/2022	N/A	-65	-57	-57	N/A
6/30/2022	N/A	-66	-53	-53	N/A
3/31/2022	N/A	-63	-42	-42	N/A
12/31/2021	N/A	-58	-43	-43	N/A
9/30/2021	N/A	-53	-39	-39	N/A
6/30/2021	N/A	-46	-37	-37	N/A
3/31/2021	N/A	-39	-36	-36	N/A
12/31/2020	N/A	-38	-37	-37	N/A
9/30/2020	N/A	-39	-40	-40	N/A
6/30/2020	N/A	-49	-42	-42	N/A
3/31/2020	N/A	-55	-48	-48	N/A
12/31/2019	N/A	-61	-45	-45	N/A
9/30/2019	N/A	-58	-42	-42	N/A
6/30/2019	N/A	-50	-41	-41	N/A
3/31/2019	N/A	-46	-35	-35	N/A
12/31/2018	N/A	-39	-30	-30	N/A
9/30/2018	N/A	-35	-27	-27	N/A
6/30/2018	N/A	-29	-24	-24	N/A
3/31/2018	N/A	-26	N/A	-23	N/A
12/31/2017	N/A	-22	N/A	-19	N/A
9/30/2017	N/A	-20	N/A	-18	N/A
6/30/2017	N/A	-20	N/A	-17	N/A
3/31/2017	N/A	-19	N/A	-15	N/A
12/31/2016	N/A	-19	N/A	-15	N/A
9/30/2016	N/A	-18	N/A	-14	N/A
6/30/2016	N/A	-17	N/A	-14	N/A
3/31/2016	N/A	-15	N/A	-12	N/A
12/31/2015	N/A	-12	N/A	-9	N/A
9/30/2015	N/A	-10	N/A	-8	N/A
6/30/2015	N/A	-9	N/A	-6	N/A
3/31/2015	N/A	-12	N/A	-6	N/A
12/31/2014	N/A	-10	N/A	-5	N/A
9/30/2014	N/A	-6	N/A	-4	N/A
6/30/2014	N/A	-3	N/A	-3	N/A
3/31/2014	N/A	5	N/A	-2	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ALDX devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: ALDX devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: ALDX devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ALDX ( 49.4% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ALDX ( 49.4% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: ALDX devrait être non rentable dans 3 ans.

Aldeyra Therapeutics Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.1% to US$10.00

Consensus EPS estimates fall by 209%

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Recent updates

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment